NHS NEL
Demonstration Formulary
Demonstration Formulary
6 Endocrine system
06-01-02-03 Thiazolidinediones
| Pioglitazone |
|
Formulary
|
 MHRA: Insulin combined with pioglitazone: risk of cardiac failure MHRA: Pioglitazone: risk of bladder cancer NICE NG28: Type 2 diabetes in adults: management |
|
Links
- DVLA guidance
- How to use Trulicity Pen - Video
- How to use Victoza Pen - Video
- MHRA Alert: SGLT2 inhibitors: monitor ketones in blood during treatment interruption for surgical procedures or acute serious medical illness
- MHRA Alert: SGLT2 inhibitors: monitor ketones in blood during treatment interruption for surgical procedures or acute serious medical illness
- MHRA Alert: SGLT2 inhibitors: monitor ketones in blood during treatment interruption for surgical procedures or acute serious medical illness
- MHRA Alert: SGLT2 inhibitors: monitor ketones in blood during treatment interruption for surgical procedures or acute serious medical illness
- MHRA Alert: SGLT2 inhibitors: reports of Fourniers gangrene (necrotising fasciitis of the genitalia or perineum) (Feb 2019)
- MHRA Alert: SGLT2 inhibitors: reports of Fourniers gangrene (necrotising fasciitis of the genitalia or perineum) (Feb 2019)
- MHRA Alert: SGLT2 inhibitors: reports of Fourniers gangrene (necrotising fasciitis of the genitalia or perineum) (Feb 2019)
- MHRA Alert: SGLT2 inhibitors: reports of Fourniers gangrene (necrotising fasciitis of the genitalia or perineum) (Feb 2019)
- MHRA Exenatide alert
- MHRA: Canagliflozin (Invokana, Vokanamet): signal of increased risk of lower extremity amputations observed in trial in high cardiovascular risk patients
- MHRA: Dipeptidylpeptidase-4 inhibitors: risk of acute pancreatitis
- MHRA: Dipeptidylpeptidase-4 inhibitors: risk of acute pancreatitis
- MHRA: Dipeptidylpeptidase-4 inhibitors: risk of acute pancreatitis
- MHRA: Dipeptidylpeptidase-4 inhibitors: risk of acute pancreatitis
- MHRA: Dipeptidylpeptidase-4 inhibitors: risk of acute pancreatitis
- MHRA: Dipeptidylpeptidase-4 inhibitors: risk of acute pancreatitis
- MHRA: Dipeptidylpeptidase-4 inhibitors: risk of acute pancreatitis
- MHRA: Exenatide (Byetta ▼): risk of severe pancreatitis and renal failure
- MHRA: Insulin combined with pioglitazone: risk of cardiac failure
- MHRA: Insulin combined with pioglitazone: risk of cardiac failure
- MHRA: Pioglitazone: risk of bladder cancer
- MHRA: Pioglitazone: risk of bladder cancer
- MHRA: SGLT2 inhibitors (canagliflozin, dapagliflozin, empagliflozin): risk of diabetic ketoacidosis
- MHRA: SGLT2 inhibitors (canagliflozin, dapagliflozin, empagliflozin): risk of diabetic ketoacidosis
- MHRA: SGLT2 inhibitors (canagliflozin, dapagliflozin, empagliflozin): risk of diabetic ketoacidosis
- MHRA: SGLT2 inhibitors (canagliflozin, dapagliflozin, empagliflozin): risk of diabetic ketoacidosis
- MHRA: SGLT2 inhibitors: updated advice on increased risk of lower-limb amputation (mainly toes)
- MHRA: SGLT2 inhibitors: updated advice on increased risk of lower-limb amputation (mainly toes)
- NICE CG 28 Type 2 diabetes in adults: management NICE guideline
- NICE Guidance on prescribing
- NICE NG18: Diabetes (type 1 and type 2) in children and young people: diagnosis and management
- NICE NG19: Diabetic foot problems: prevention and management
- NICE NG28: Type 2 diabetes in adults: management
- NICE NG28: Type 2 diabetes in adults: management
- NICE NG28: Type 2 diabetes in adults: management
- NICE NG28: Type 2 diabetes in adults: management (Dec 2015)
- NICE NG28: Type 2 diabetes in adults: management (Dec 2015)
- NICE NG28: Type 2 diabetes in adults: management (Dec 2015)
- NICE NG28: Type 2 diabetes in adults: management (Dec 2015)
- NICE NG3: Diabetes in pregnancy: management from preconception to the postnatal period
- NICE TA203: Diabetes (type 2) - liraglutide
- NICE TA288: Dapagliflozin in combination therapy for treating type 2 diabetes
- NICE TA288: Dapagliflozin in combination therapy for treating type 2 diabetes
- NICE TA315: Canagliflozin in combination therapy for treating type 2 diabetes
- NICE TA336: Empagliflozin in combination therapy for treating type 2 diabetes
- NICE TA336: Empagliflozin in combination therapy for treating type 2 diabetes
- NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes
- NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes
- NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes
- NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes
- NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes
- NICE TA418: Dapagliflozin in triple therapy for treating type 2 diabetes
- NICE TA418: Dapagliflozin in triple therapy for treating type 2 diabetes
- NICE TA572: Ertugliflozin as monotherapy or with metformin for treating type 2 diabetes
- NICE TA583: Ertugliflozin with metformin and a dipeptidyl peptidase-4 inhibitor for treating type 2 diabetes
- NICE TA622: Sotagliflozin with insulin for treating type 1 diabetes
- NICE TA664: Liraglutide for managing overweight and obesity
- NICE TA664: Liraglutide for managing overweight and obesity
- NICE TA679: Dapagliflozin for treating chronic heart failure with reduced ejection fraction
- NICE TA773: Empagliflozin for treating chronic heart failure with reduced ejection fraction
- NICE TA775: Dapagliflozin for treating chronic kidney disease
- TA63: Glitazones in the treatment of type 2 diabetes (Review of TA9 and TA21)